Mr Peter Mullen
Research Fellow
Research areas
I am a Research Fellow working with Professor David Harrison. My current research interests are in establishing primary tumouroids from both renal and colorectal cancers using fresh tissue obtained from patients undergoing surgery. Methodolgy includes the use spinner flasks and / or microfluidic devices to establish 3D cultures (tumouroids) which, after treatment with either conventional or protide-modified drugs, can be collected and analysed by conventional techniques including immunofluorescence (IF).
Selected publications
-
Open access
Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine
Patel, D., Dickson, A., Zickuhr, G. M., Um, I. H., Read, O. J., Melo Czekster, C., Mullen, P., Harrison, D. J. & Bre, J. L., 1 Dec 2024, In: Translational Oncology. 50, 11 p., 102114.Research output: Contribution to journal › Article › peer-review
-
Open access
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent
Bré, J. L., Dickson, A., Read, O. J., Zhang, Y., McKissock, F. G., Mullen, P., Tang, P., Zickuhr, G. M., Melo Czekster, C. & Harrison, D. J., 31 Mar 2023, In: Cancer Chemotherapy and Pharmacology. 12 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer model
Moore, K. M., Cerqueira, V., MacLeod, K. G., Mullen, P., Hayward, R. L., Green, S., Harrison, D. J., Cameron, D. A. & Langdon, S. P., 28 Feb 2022, (E-pub ahead of print) In: Exploration of Targeted Anti-tumor Therapy. 3, p. 97-116 20 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In: Scientific Reports. 9, 13 p., 7643.Research output: Contribution to journal › Article › peer-review
-
Open access
A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J., May 2017, In: Oncotarget. 8, 18, p. 29657-29667 11 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells
Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S., 2017, In: Oncotarget. 8, 26, p. 42857-42875Research output: Contribution to journal › Article › peer-review
-
Open access
Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer
Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M., 26 Jun 2017, In: BMC Medicine. 15, 12 p., 118.Research output: Contribution to journal › Article › peer-review
-
Open access
Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models
Martínez-Pérez, C., Ward, C., Turnbull, A. K., Mullen, P., Cook, G., Meehan, J., Jarman, E. J., Thomson, P. I. T., Campbell, C. J., McPhail, D., Harrison, D. J. & Langdon, S. P., 13 Apr 2016, In: British Journal of Cancer. 114, 8, p. 905-916Research output: Contribution to journal › Article › peer-review
-
Open access
Total synthesis of dehaloperophoramidine using a highly diastereoselective Hosomi-Sakurai reaction
Wilkie, R. P., Neal, A., Johnston, C. A., Voûte, N., Lancefield, C. S., Stell, M., Medda, F., Makiyi, E. F., Turner, E., Ojo, O. S., Slawin, A. M. Z., Lebl, T., Mullen, P., Harrison, D. J., Ireland, C. M. & Westwood, N. J., 14 Sept 2016, In: Chemical Communications. 52, 71, p. 10747-10750Research output: Contribution to journal › Article › peer-review
-
Open access
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models
Ward, C., Meehan, J., Mullen, P., Supuran, C., Dixon, J. M., Thomas, J. S., Winum, J.-Y., Lambin, P., Dubois, L., Pavathaneni, N.-K., Jarman, E. J., Renshaw, L., Um, I. H., Kay, C., Harrison, D. J., Kunkler, I. H. & Langdon, S. P., 2015, In: Oncotarget. 6, 28, p. 24865-24870 15 p.Research output: Contribution to journal › Article › peer-review